| everolimus / Generic mfg. |
NCT03491371: Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use |
|
|
| Completed | N/A | 56 | RoW | Methylsulfonic apatinib | Peking University People's Hospital, Peking University Shougang Hospital, Peking University International Hospital | Efficacy, Toxicity | 12/16 | 02/17 | | |
NCT03493165: Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) |
|
|
| Available | N/A | | NA | Everolimus, Zortress, Afinitor, and Afinitor Disperz | The University of Texas Health Science Center at San Antonio | Uterine Sarcoma | | | | |
NCT03493152: Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019) |
|
|
| Temporarily Not Available | N/A | | NA | Everolimus, Zortress, Afinitor, and Afinitor Disperz | The University of Texas Health Science Center at San Antonio | Gastrointestinal Stromal Tumor | | | | |
ChiCTR2000036618: Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study |
|
|
| Not yet recruiting | N/A | 18 | | Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21，28-day cycle ;Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle ;Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8， 21-days cycle | Shanghai General Hospital; Shanghai General Hospital, Project special fund | osteosarcoma | | | | |
| Active, not recruiting | N/A | 682 | Europe | Blood sampling, Tumor sampling, Stool sampling | Institut Curie | Cancer | 09/24 | 09/25 | | |
| Recruiting | N/A | 330 | Europe | Blood sampling to build population pharmacokinetics model | UNICANCER | Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors | 08/26 | 06/27 | | |
